培美曲塞注射剂联合顺铂注射剂治疗非小细胞肺癌的临床疗效研究

Clinical trial of pemetrexed injection combined with cisplatin injection in the treatment of non-small cell lung cancer

目的观察培美曲塞注射剂联合顺铂注射剂治疗非小细胞肺癌的临床疗效及安全性。方法将42例非小细胞肺癌患者随机分为对照组21例和试验组21例。对照组予以静脉滴注500 mg·m^(-2)培美曲塞(第1天);试验组予以静脉滴注500 mg·m^(-2)培美曲塞(第1天),30 min后,静脉滴注25 mg·m^(-2)顺铂(第1~3天)。2组患者1个疗程均为3周,共治疗2个疗程。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为52.38%(11例/21例)和23.81%(5例/21例),差异有统计学意义(P<0.05)。试验组发生的药物不良反应为发热,对照组发生的药物不良反应有血小板减少、发热和皮疹。试验组和对照组的总药物不良反应发生率分别为47.62%和57.14%,差异无统计学意义(P>0.05)。结论培美曲塞注射剂联合顺铂注射剂治疗非小细胞肺癌的临床疗效确切,且不增加药物不良反应的发生率。

Objective To observe the clinical efficacy and safety of pemetrexed injection combined with cisplatin injection in the treatment of non- small cell lung cancer. Methods Forty -two patients with non - small cell lung cancer were randomly divided into control group and treat- ment group with 21 cases per group. Control group was given intravenous infusion of 500 mg · m-2 pemetrexed （day 1 ）. Treatment group were given intravenous infusion of 500 mg · m-2 pemetrexed （day 1 ） and in- travenous infusion of 25 mg ·m -2 cisplatin （ day l - 3 ） after 30 min. Two groups were treated for two cycles with 3 weeks per cycle. The clini- cal efficacy and adverse drug reactions were compared between two groups. Results After treatment, the total effective rates of the treat- ment and control groups were 52.38% （ll cases/21 cases） and 23.81% （5 cases/21 cases） with significant difference （P 〈 0. 05 ）. The adverse drug reactions of treatment group were based on fever, which in control group were based on thrombocytopenia, fever and rash. The to- tal incidences of adverse drug reactions in the treatment and control groups were 47.62% and 57. 14% without significant difference （ P 〉0. 05 ） . Conclusion Pemetrexed injection combined with cisplatin injection has a definitive clinical efficacy in the treatment of non - small cell lung cancer, without increasing the incidence of adverse drug reactions.